Tags : Adult Patients

Amicus Therapeutics’ Galafold (migalastat) Receives FDA Approval for Fabry Disease

Vartika Singh August 10, 2018

Shots: The approval is based on P-III FACET or Study 011 results assessing Galafold (150mg) in patient with Fabry Disease, evaluating its safety and efficacy The FACET or Study 011 […]readmore

Tags : Adult Patients

Amicus Therapeutics’ Galafold (migalastat) Receives FDA Approval for Fabry Disease

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Adult Patients

﻿Amicus Therapeutics’ Galafold (migalastat) Receives FDA Approval for Fabry Disease

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company

Amicus Therapeutics’ Galafold (migalastat) Receives FDA Approval for Fabry Disease